CN107242576A - 一种即冲即食的孕妇及乳母用营养补充剂制品及其制备方法 - Google Patents
一种即冲即食的孕妇及乳母用营养补充剂制品及其制备方法 Download PDFInfo
- Publication number
- CN107242576A CN107242576A CN201710437705.3A CN201710437705A CN107242576A CN 107242576 A CN107242576 A CN 107242576A CN 201710437705 A CN201710437705 A CN 201710437705A CN 107242576 A CN107242576 A CN 107242576A
- Authority
- CN
- China
- Prior art keywords
- nutrient
- pregnant woman
- nutritious supplementary
- supplementary pharmaceutical
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008935 nutritious Nutrition 0.000 title claims abstract description 72
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 15
- 229940127557 pharmaceutical product Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 235000015097 nutrients Nutrition 0.000 claims abstract description 66
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 63
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 239000000463 material Substances 0.000 claims abstract description 42
- 239000011261 inert gas Substances 0.000 claims abstract description 26
- 239000000047 product Substances 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 238000007789 sealing Methods 0.000 claims abstract description 18
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 86
- 235000018102 proteins Nutrition 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 42
- 235000010469 Glycine max Nutrition 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 29
- 239000000706 filtrate Substances 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 27
- 239000002994 raw material Substances 0.000 claims description 27
- 235000016709 nutrition Nutrition 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 21
- 239000001569 carbon dioxide Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 21
- 231100000252 nontoxic Toxicity 0.000 claims description 21
- 230000003000 nontoxic effect Effects 0.000 claims description 21
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 claims description 20
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 20
- 238000002161 passivation Methods 0.000 claims description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 18
- 244000068988 Glycine max Species 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 16
- 238000009835 boiling Methods 0.000 claims description 16
- 229910052742 iron Inorganic materials 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 13
- 239000011669 selenium Substances 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 239000004743 Polypropylene Substances 0.000 claims description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 239000007791 liquid phase Substances 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 12
- 229910052725 zinc Inorganic materials 0.000 claims description 12
- -1 polypropylene Polymers 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 239000004698 Polyethylene Substances 0.000 claims description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 229920000573 polyethylene Polymers 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- 229910052711 selenium Inorganic materials 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 claims description 8
- 102000003820 Lipoxygenases Human genes 0.000 claims description 8
- 108090000128 Lipoxygenases Proteins 0.000 claims description 8
- 108010073771 Soybean Proteins Proteins 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 8
- 235000012054 meals Nutrition 0.000 claims description 8
- 235000019161 pantothenic acid Nutrition 0.000 claims description 8
- 239000011713 pantothenic acid Substances 0.000 claims description 8
- 229940055726 pantothenic acid Drugs 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 235000019710 soybean protein Nutrition 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 229920001155 polypropylene Polymers 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 239000004715 ethylene vinyl alcohol Substances 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- 239000008393 encapsulating agent Substances 0.000 claims description 4
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 4
- 235000004252 protein component Nutrition 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019158 vitamin B6 Nutrition 0.000 claims description 4
- 239000011726 vitamin B6 Substances 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229920006248 expandable polystyrene Polymers 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 230000000050 nutritive effect Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 101000576320 Homo sapiens Max-binding protein MNT Proteins 0.000 claims 1
- 239000004677 Nylon Substances 0.000 claims 1
- 229920006121 Polyxylylene adipamide Polymers 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229920001778 nylon Polymers 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 abstract description 3
- 210000003754 fetus Anatomy 0.000 description 31
- 235000013305 food Nutrition 0.000 description 27
- 230000035935 pregnancy Effects 0.000 description 21
- 239000002775 capsule Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 230000035764 nutrition Effects 0.000 description 13
- 208000007502 anemia Diseases 0.000 description 12
- 239000013589 supplement Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000007908 dry granulation Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000001605 fetal effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000002950 deficient Effects 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 235000014347 soups Nutrition 0.000 description 7
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000004411 aluminium Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920002799 BoPET Polymers 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010046334 Urease Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000004641 brain development Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 229920000007 Nylon MXD6 Polymers 0.000 description 3
- 206010033546 Pallor Diseases 0.000 description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 3
- 206010036600 Premature labour Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 208000007287 cheilitis Diseases 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 208000026440 premature labor Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000005232 Glossitis Diseases 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000018773 low birth weight Diseases 0.000 description 2
- 231100000533 low birth weight Toxicity 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000013021 overheating Methods 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 108010048090 soybean lectin Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 208000002254 stillbirth Diseases 0.000 description 2
- 231100000537 stillbirth Toxicity 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005176 Blindness congenital Diseases 0.000 description 1
- 206010070817 Bone decalcification Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 208000006893 Fetal Hypoxia Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010072665 Tooth demineralisation Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003167 anti-vitamin Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004179 neuropil Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000021485 packed food Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000033504 synapse organization Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
- B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
- B65D81/2069—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere
- B65D81/2076—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere in an at least partially rigid container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- B65D85/70—Containers, packaging elements or packages, specially adapted for particular articles or materials for materials not otherwise provided for
- B65D85/804—Disposable containers or packages with contents which are mixed, infused or dissolved in situ, i.e. without having been previously removed from the package
- B65D85/816—Disposable containers or packages with contents which are mixed, infused or dissolved in situ, i.e. without having been previously removed from the package into which liquid is added and the resulting preparation is retained, e.g. cups preloaded with powder or dehydrated food
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mechanical Engineering (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于,是由营养补充剂和耐高温材料组成的容器构成;所述营养补充剂放入耐高温材料容器内,密封容器,容器内充填满惰性气体;所述营养补充剂成分重量比为:优质蛋白质18~35份,营养素1‑10份,辅料50‑84份,该制品即冲即食,安全方便,吸收更好,制备方法简单,适合工业化生产。
Description
技术领域
本发明涉及保健品领域,特别涉及即冲即食的孕妇及乳母用营养补充剂。
背景技术
市面上现有的孕妇及乳母奶粉是孕妇、哺乳期妇女改善营养状况的措施,作为膳食多样化的组成部分或者额外补充,满足目标人群孕期、哺乳期对营养素的额外需求。孕妇及乳母奶粉属于调制乳粉,应符合GB19644《食品安全国家标准乳粉》的要求,企业可以根据GB14880《食品安全国家标准食品营养强化剂使用标准》的要求,自愿在产品中强化某些营养素。该类产品的标签应符合GB7718《食品安全国家标准预包装食品标签通则》和GB28050《食品安全国家标准预包装食品营养标签通则》的要求。
本发明涉及一种安全的、即冲即食性孕妇及乳母营养补充剂胶囊及其相应的制备方法,是一种以补充蛋白质和微量营养素为目的的食品,是一种高密度的营养补充食品,产品中微量营养素含量要求显著高于强化的孕妇及乳母奶粉。该类食品属于特殊膳食用食品类别,可以为孕妇及乳母补充优质蛋白质和多种微量营养素,其产品中营养素含量是根据《中国居民膳食营养素参考摄入量2013》,结合目标人群的膳食营养素摄入量数据等确定的。该类产品的技术指标应符合GB 31601《食品安全国家标准-孕妇及乳母营养补充食品》的要求,其标签应符合GB13432《食品安全国家标准-预包装特殊膳食用食品标签》的要求。安全的、即冲即食性孕妇及乳母营养补充剂胶囊为目标人群提供一种蛋白质及其它需要的营养素的补充方法,可作为孕妇及乳母营养改善的安全、方便方法之一,保障孕妇及乳母的营养需求和食用安全,将会对我国孕妇及乳母的营养改善起到一定作用。
发明内容
本发明的目的在于提供一种针对我国孕妇及乳母存在的优质蛋白质和多种微量营养素摄入不足等营养相关问题而生产加工而成的一种即冲即食的特殊膳食用食品,添加优质蛋白质和多种微量营养素(维生素和矿物质等),以满足孕期妇女自身以及胎儿营养的特殊需求,满足产后妇女自身以及婴儿营养的特殊需求,对孕妇及乳母优质蛋白质和各种微量营养素的补充将起到非常重要的作用,促进胎儿或婴儿正常发育,预防和减少孕期并发症和低出生体重儿等问题的发生。有助于乳母产后身体恢复及乳汁分泌,促进新生儿健康发育。本发明的另一目的在于提供即冲即食的孕妇及乳母用营养补充剂的制备方法。
为实现上述目的,本发明是通过下述技术方案实现的:
本发明的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于,是由营养补充剂和耐高温材料组成的容器构成;所述营养补充剂放入耐高温材料容器内,密封容器,容器内充填满惰性气体;所述营养补充剂包括下述重量份成分:
优质蛋白质
营养素 1-10份,
辅料 35-84份。
进一步优选,本发明营养补充剂包括下述重量百分比成分:
优质蛋白质 25-30份,
营养素 2-5份,
辅料 50-69份。
本发明所述优质蛋白质中无腥味、不应含有抗营养因子。
本发明所述的优质蛋白质应来源于大豆蛋白粉、大豆蛋白粉制品、乳类、乳制品中的一种或一种以上,优选大豆蛋白粉。
本发明所述营养素包括核心营养素(必须有的)和选择性营养素。所述的核心营养素的组成见下表1:
表1核心营养素
核心营养素 | 孕妇用(每日μg) | 乳母用(每日μg) |
维生素A | 230-700 | 400-1200 |
维生素D | 3-10 | 3-10 |
维生素B12 | 1.2-4.8 | 1.3-5.2 |
叶酸 | 140-400 | 130-400 |
铁 | 9000-18000 | 7000-16000 |
所述选择性营养素包括表2中的一种以上。
表2选择性营养素
进一步优选,所述核心营养素优选重量比见表3:
表3核心营养素优选重量比
核心营养素 | 孕妇用(每日μg) | 乳母用(每日μg) |
维生素A | 400-600 | 800-1000 |
维生素D | 6-8 | 8-10 |
维生素B12 | 3.6-4.0 | 4.0-5.0 |
叶酸 | 300-400 | 300-400 |
铁 | 15000-16000 | 14000-15000 |
进一步优选,所述选择性营养素优选重量比见表4
表4选择性营养素优选重量比:
选择性营养素 | 孕妇(每日μg) | 乳母(每日μg) |
维生素E(а-TE) | 10000-12000 | 12000-15000 |
维生素K | 50-70 | 60-80 |
维生素B1 | 2000-2500 | 2500-2800 |
维生素B2 | 2000-2400 | 2000-2800 |
维生素B6 | 3800-4200 | 2800-3000 |
维生素C | 180-200 | 200-260 |
烟酸(烟酰胺) | 12000-15000 | 12000-16000 |
泛酸 | 8000-10000 | 10000-12000 |
胆碱 | 600000-800000 | 800000-1000000 |
生物素 | 50-70 | 60-80 |
二十二碳六烯酸 | 120000-160000 | 120000-180000 |
钙 | 400000-600000 | 500000-800000 |
镁 | 250000-300000 | 250000-300000 |
锌 | 5000-8000 | 7000-10000 |
硒 | 30-45 | 45-60 |
本发明所述的大豆蛋白粉腥味是由大豆蛋白粉中脂肪氧化酶氧化多价不饱和脂肪酸(主要包括亚油酸、亚麻酸等)后生成的一类醇、醛、酮和酸等低分子挥发性气体所致,而这些小分子化合物大部分都具有不同程度的异味,即形成了大豆不同的腥味。大豆蛋白粉腥味直接限制了大豆蛋白粉的广泛食用。孕妇和乳母更加难以接受大豆蛋白粉腥味,直接限制了孕妇和乳母的食用。
本发明所述抗营养因子是指对营养物质的消化、吸收和利用产生不利影响以及使人和动物产生不良反应的物质包括胰蛋酶抑制物、植物红细胞凝集素(Phytohemagglutinin,PHA)、大豆凝集素、抗原蛋白、单宁、皂苷、植酸磷、大豆寡糖、异黄酮、抗维生素因子——脂肪氧化酶(简称Lox)、脲酶中一种或几种。
所述胰蛋酶抑制因子能够降低胰糜蛋白酶活性,生长迟缓,胰腺增生肿大。所述植物红细胞凝集素包括大豆凝集素,可使肠壁损伤,免疫反应,增加内源氮排出量,增加内源蛋白内分泌。所述抗原蛋白免疫反应影响肠壁完整性。所述单宁通过形成蛋白质碳水化合物复合物,影响蛋白质和碳水化合物的消化。皂苷可溶血,并影响肠道渗透性。植酸磷与蛋白质和微量元素形成复合物,影响蛋白质和碳水化合物的消化。所述的大豆寡糖可胀气、腹泻,影响养分消化。所述异黄酮能抑制生产,并使子宫增大。所述抗微生物因子能够对微生物的利用,引起维生素缺乏症。
上述营养补充剂中,各种营养素及其添加量也是通过筛选的。
所述维生素A:妊娠期内胎儿机体生长发育以及母体各组织的增加和物质储备均需要大量的维生素A。动物研究发现:妊娠期维生素A缺乏,可引起流产、胚胎发育不良,幼年动物生长停滞及骨、齿形成不良。维生素A严重不足时,可导致动物骨骼和其他器官畸形。但摄入过量的维生素A,同样有可能引起胎儿畸形和影响胎儿的正常发育。
维生素D:孕妇缺乏维生素D缺乏不仅影响自身怀孕及生产过程中的健康状况,也可能影响胎儿及新生儿的生长发育及骨骼钙化,并对成人后的健康产生长远影响。
叶酸:叶酸是一种水溶性B族维生素,孕妇对叶酸的需求量比正常人高4倍,孕早期是胎儿器官***分化,胎盘形成的关键时期,细胞生长,***十分旺盛。此时叶酸缺乏可导致胎儿畸形。
维生素B12:妇女妊娠期消化吸收功能增强,需要量增加,孕妇如果缺乏维生素B12,可发生营养性大细胞贫血,新生儿也可患贫血。所以,维生素B12对孕妇十分重要。
铁:铁是人体生成红细胞的主要原料之一,怀孕后新陈代谢加快,铁需要量增加,孕期的缺铁性贫血,不但可以导致孕妇出现心慌气短、头晕、乏力,还可导致胎儿宫内缺氧,生长发育迟缓,生后智力发育障碍,生后6个月之内易患营养性缺铁性贫血等。孕妇要为自己和胎儿在宫内及产后的造血做好充分的铁储备,因此,在孕期应特别注意补充铁剂。孕期对各种营养的需求增加,尤其是铁。除了维持自身的需要外,还要为胎儿生长提供铁,用以供给胎儿血液和组织细胞日益增长的需要,并有相当数量贮存于胎儿肝脏内。如果孕妇发生缺铁性贫血,不仅容易在分娩时发生各种合并症,对胎儿的影响更大,例如导致胎儿宫内发育迟缓、低出生体重、早产、死产、新生儿死亡等。此外,还会影响到胎儿免疫***的发育。因此,孕期补充一定剂量的铁很有必要。
维生素E(或а-生育酚):孕妇缺乏维生素E的话很容易引起胎动不安、流产后不易再受孕,或导致皮肤早衰、毛发脱落等症状。
维生素K:妊娠期如果缺乏维生素K,其流产率增加,即使存活,由于其体内凝血酶低下,易出血,或者引起胎儿先天性失明和智力发育迟缓及死胎。因此,孕妇应注意摄食富含维生素K的食物,以预防产后新生儿因维生素K缺乏引起颅内、消化道出血等。
维生素B1:维生素B1为水溶性,在人体内除肠内细菌可合成一部分外,人体自身不能合成维生素B1,主要来源于食物。缺乏维生素B1的孕妇会使新生儿息先天性脚气病,出生时全身水肿,体温低,吸吮无力,经常呕吐,肢体无力,终日昏睡或者哭声微弱,夜啼。
维生素B2:准妈妈在孕初期如果缺乏维生素B2,会通过影响烟酸的代谢,进而影响胎儿神经***的发育,造成神经***畸形。同时还会影响蛋白质代谢及胎儿发育,可使胎儿软骨形成受阻,发生骨骼畸形,如长骨缩短、肋骨融合等症状。如果要在孕末期缺乏维生素B2,可引起口角炎、舌炎、唇炎,会使早产儿发生率增高,未成熟儿和死产儿增多。
维生素B6:维生素B6对各种原因的引起的呕吐,尤其是妊娠呕吐有很好的治疗效果,因为它参与女性体内蛋白质,脂肪、碳水化合物及某些激素的代谢,孕妇需要服用VB6时,一定要适量服用。这样既对自身有益,有对胎儿有利。
烟酸(或烟酰胺):烟酸就是维生素B3,或维生素PP,若其缺乏时,可产生糙皮病,表现为皮炎、舌炎、口咽、腹泻及烦躁、失眠感觉异常等症状。可以促进消化***的健康,减轻胃肠障碍、使皮肤更健康、预防和缓解严重的偏头痛、促进血液循环,使血压下降、减轻腹泻现象、减轻美尼尔氏症(Menieres syndrome)的不适症状;使人体能充分地利用食物来增加能量、治疗口腔、嘴唇炎症,防止口臭、降低胆固醇及甘油三脂。
泛酸:泛酸就是维生素B5、遍多酸,是一种水溶性B族维生素,泛酸具制造抗体功能,在维护头发、皮肤及血液健康方面亦扮演重要角色;一般公认泛酸与头发、皮肤的营养状态密切相关,当头发缺乏光泽或变得较稀疏是,多补充泛酸当可见其效。主要功能可以制造及更新身体组织、帮助伤口愈合、制造抗体,抵抗传染病、防止疲劳,帮助抗压、缓和多种抗生素副作用及毒素、舒缓恶心症状。
胆碱:而对孕妇来说,胆碱的摄入量是否足够,则会影响到胎儿的大脑发育。从怀孕25周开始,主管人们记忆的海马体开始发育,并一直持续到孩子4岁。所以,如果在海马体发育初期,孕妇出现胆碱缺乏,就会导致胎儿的神经细胞凋亡,新生脑细胞减少,进而影响到大脑发育。
生物素:生物素,也称为维生素h,是我们人体重要的营养元素,如果人体缺乏生物素,会患上一系列的疾病,给患者的健康带来很大的影响。研究发现大约有50%的孕妇缺乏生物素。由于她们缺乏告知身体如何正确使用生物素的一种酶,并因此导致代谢功能降低。但,孕妇也不宜服用过量生物素,因为有导致流产的风险。
维生素C:维生素c可以提高胎宝宝的脑功能敏锐性,并对胎宝宝的造血***健全和机体抵抗力的增强有促进作用。如果准妈妈孕期严重缺乏维生素C,则易患坏血病。合理的补充维生素C对孕妇本身和胎儿都是非常重要的。因为维生素C是胎儿生长发育过程中必不可缺的营养素之一,特别是在怀孕中期胎儿生长发育迅速,需要补充足够的维生素。妊娠过程中母体血液中的维生素c含量是逐渐下降的,分娩时仅为孕早期的一半,这时严重摄入不足的准妈妈容易发病,所以说维生素C的补充要及时。
二十二碳六烯酸:有“脑黄金”之称的DHA(二十二碳六烯酸),为神经突触发育所必需,对胎儿脑和神经发育有益,有助于婴儿的大脑、神经发育,有利于婴儿的视力。
钙:人体很需要无机盐(矿物质),准妈妈更不可缺,特别是钙的作用更为重要。每个孕妇都需要补钙,孕妇在整个怀孕期间需要40克钙,在孕晚期,有些孕妇出现下肢抽筋。由于胎儿骨组织的生成和发育及母亲生理代谢均需要大量的钙,如果饮食中钙的含量不足或缺乏日照等,都会导致准妈妈血钙下降。因为胎儿所需的钙只有从母体中获得,所以,即使母体缺钙,胎儿仍然要从母体中吸取定量的钙,这就可能导致准妈妈骨骼和牙齿脱钙,引起腰病、腿病、骨头痛、手足抽搐及牙齿脱落等,严重时还会发生骨软化症、骨盆变形,甚至造成难产。钙对神经***也很重要,当血清中钙含量减少时,准妈妈神经兴奋性增高,于是肌肉发生抽搐,这就是平常所说的“抽筋”。同时,胎儿缺钙可导致胎儿骨骼发育不良,引起先天性佝偻病等。所以,孕期及时补钙是相当重要的。
镁:镁对人体的功用:镁离子主要的功能在于让受伤的细胞得以修复,另外,它也能让骨骼和牙齿生成更坚固、调整胆固醇以及促进胎儿的脑部发育。医师说,镁还有一个特点,就是怀孕期间如果有妊娠高血压,医师在控制病情时,会在点滴中加入一点点镁,让肌肉达到放松目的。若孕妇含镁量太低,容易引发子宫收缩,造成早产。相反的,孕妇镁含量太高,就容易造成镁中毒,严重者,还有可能抑制孕妇呼吸和心跳,所以补充镁时要特别注意。
锌:怀孕期间,胎儿对锌的需要量迅速增加,因此孕妇需要增加锌的补充,以保证母体锌营养平衡和孩子的正常发育。事实上,锌对胎儿智力发育的影响从最初就开始了。我们知道,胎儿发育最先是受精卵通过有丝***进行增殖,在子宫内逐渐发育成组织和器官,而有丝***的前提是DNA复制和RNA转录,锌则是DNA复制、RNA转录和核酸合成所需酶的必需组成成分。妊娠头3个月,胎儿对各种理化因素非常敏感,如果妊娠期妇女缺锌,很容易导致胎儿发育不良或畸形。大脑是胎儿所有器官中发育最早最快的一个器官,母亲怀孕18天,在胚胎里就可辨认出神经丛;怀孕后期,胎儿大脑平均每分钟将分化增殖近2万个神经细胞。由于锌能促进脑神经细胞的***、生长和再生,因此如果孕妇因锌营养状况不良而造成胎儿脑神经细胞数量减少,这种影响将是无法挽回的。据报道,锌缺乏的胎儿,在出生后有30%为智力低下。
硒:美国医学工作者在研究硒与妊娠期、哺乳期妇女及新生儿的关系时,发现硒可降低孕妇血压,消除水肿,改善血管症状,预防和治疗妊娠高血压症,抑制妇科肿瘤的恶变。此外还能预防胎儿致畸。国内的研究证实,怀孕妇女血硒含量低于非孕妇女,并且,妊娠妇女的血硒含量随妊娠期逐渐降低。分娩时降至最低点,有流产、早产、死胎等妊娠病史的孕妇血硒含量又明显低于无此病史者。德意志联邦大学儿重医院的研究表明,婴儿出生时,血硒水平很低,需及时从母乳中摄取大量的硒,以保证婴儿正常的生长发育。预防新生儿的营养阻滞和保证大脑的正常发育,这就使母乳的硒含量显得极为重要。因此,妊娠期和哺乳期妇女每日补充适量的硒,对新生儿及自身的健康是十分有益的。孕妇怎么补硒好,量一定要适当,如果超过人体所需,就可能会引发肺炎,肝、肾功能退化等病症,并危及胎儿的生命。如果摄入大量的硒,也会给身体造成严重危害。
所述辅料包括于蔗糖、乳糖、葡萄糖、淀粉、纤维素等。
所述孕妇及乳母营养补充剂以颗粒、粉末或膏剂等易冲泡形式存在。
本发明所述的耐高温材料的容器,该容器的器壁被压制成具有特殊“倒人字型”内陷结构,容器的底部被压制成具有特殊螺旋状内陷结构,通过热水冲头冲热水时,能产生漩涡流,有助营养补充剂粉末或颗粒的溶解和混合。
优选容器的结构包括容器本体,所述容器本体的顶部设有密封盖,底部设有出口,所述出口被密封材料密封,所述容器本体的外侧壁上设有斜凹槽和卡槽,所述容器本体的内侧壁上与所述斜凹槽相对应的部位为凸棱。
所述斜凹槽呈倒人字形布置,与所述斜凹槽相对应的凸棱也呈倒人字形布置。
所述容器本体的底部设有螺旋凹槽,所述螺旋凹槽的一端紧贴容器本体的内侧壁布置,另一端延伸至出口。
所述容器本体内的顶部和底部分别设有一过滤器。
所述密封盖包括三层密封膜,三层密封膜由内向外分别为CPP膜、铝膜和PET膜。
所述容器的的内侧壁上设有斜凸棱,当热水从顶部注入容器本体内时,热水能够沿着凸棱流动,增强了水流对内容物的搅拌作用,从而使热水与内容物混合得更加充分,避免了内容物的浪费。
本发明所述耐高温容器,其中耐高温是指温度在120℃以上,优选温度150-180℃。所述耐高温材料包括但不限于:聚乙烯PE、聚丙烯PP(熔点高达167℃)、可发性聚苯乙烯EPS(耐热变形温度达280℃以上)、PEN/PET聚乙烯萘酚树脂、含高阻隔性材料的乙烯-乙烯醇共聚物EVOH、聚偏氯乙烯PVDC、尼龙MXD6,硅氧化物蒸镀膜等的多层复合材料中的一种或几种,优选乙烯PE、聚丙烯PP,该类包装塑料除了加工性能好、没有毒性以外,最主要的特点是耐热变形温度达150℃以上,且这些材料要求在120℃、1O-20min杀菌或加热的情况下,外观形状、品质均无明显的变化、无有毒物质溶出。冲入沸腾的开水,包装盒也不会变形,因而能完全保持食品的风味。该容器具有耐高温、抗脆裂、防潮、抗氧化、耐紫外线辐射等特点,包装食品在贮存过程中不产生容器破损、内容物泄漏和微生物二次污染以及光和热使内容物变质等情况
本发明的制品的使用方法:其可放置于特殊机器里,用高压沸水冲煮,冲煮好的汤液方便流出。
本发明所述的容器本体的上下两面可被特殊结构的穿刺头刺破;可耐15BAR的沸水冲煮,实现萃取功能;容器形状使在沸水冲煮时,容器内可产生涡流,加速容器内物质的溶解;可在与之相匹配的特殊功能机器(即上面提到的设备)里旋转,带动容器内溶液旋转混合,加速容器内物质的溶解和混合均
容器本体可置于特定的机器内,通过机器的特殊装置带动容器旋转,加速容器里的内容物溶解。20-100目粒径范围的营养补充剂颗粒配合本发明特殊的容器结构在需要冲煮汤液时,把这种容器放入专用的机器内,机器的刺破针将密封盖刺破,高温高压水进入容器本体内溶解内容物,经过过滤器,进入另一端刺入容器的刺破针,通过汇集到出口,整个过程在1分钟内完成,颗粒完全溶解且无残留物。使用后的容器直接废弃,机器不直接接触里面的物质,无需清洗机器。简单方便,省时省力,无需清洗机器。
本发明还公开所述的孕妇及乳母营养补充剂制品的制备方法,包括如下步骤:
(1)无腥味、不含抗营养因子蛋白质粉制备;
(2)核心营养素预混合粉制备;
(3)选择性营养素预混合粉制备;
(4)步骤(1)蛋白质粉和步骤(2)核心营养素和步骤(3)选择性营养素混合,得粉末:
(5)制粒:步骤(4)粉末与辅料混合、制粒;
(6)灌装:将制备好的孕妇及乳母用营养补充剂颗粒装入耐高温耐高压容器内,密封。
上述步骤(1)中所述无腥味、不含抗营养因子蛋白质粉制备可采用下述两种方法。优质蛋白质粉的添加量可根据优质蛋白质粉原料中的蛋白质成分的含量,计算原料用量,所述优质蛋白质粉原料用量=蛋白质添加量÷优质蛋白质粉原料中的蛋白质成分的含量。
A.大豆蛋白粉可市购,市购的大豆蛋白粉必须符合GB/T 22493-2008要求,表5-7中所述要求。
表5大豆蛋白粉感官要求
项目 | 质量要求 |
形态 | 粉末,无结块现象 |
色泽 | 白色至浅黄色 |
气味 | 具有大豆蛋白粉固有的气味无异味 |
杂质 | 无肉眼可见的外来物质 |
表6大豆蛋白粉质量标注
表7大豆蛋白粉卫生指标
选购符合上述质量要求的大豆蛋白粉,采用物理方法消除蛋白质粉中腥味、钝化抗营养因子,优选热处理方法。热处理方法包括:
蒸汽加热处理:包括常压水蒸汽处理和高压水蒸汽处理。常压水蒸汽处理是将大豆粉碎过筛后,迅速与热蒸汽混合,使水分达到于90-100℃常压加热处理迅速降温,即可使脂肪氧化酶失活,成品风味较好,消除了蛋白质粉中腥味、钝化抗营养因子,并提高了产品的营养价值。高压水蒸汽处理是将大豆粉碎过筛后,至压力锅中,温度110-130℃、10-20分钟,压力80-110kPa,可消除蛋白质粉中腥味、钝化抗营养因子。
热风喷射钝化技术:温度为230-310℃的热风直接喷射处理大豆蛋白粉,可将脂肪氧化酶和抗营养因子钝化。
加压瞬间高温处理:当大豆粉通过管道热交换器时,将压力调至2Kg/cm2,并于130℃加热处理2秒,之后立即冷却至室温,可有效地去除豆腥味、钝化抗营养因子,而大豆蛋白基本未变性。
热水研磨处理:先将人豆浸入40℃左右的温水中,再加入热水使其温度达80-100℃,并在该温度下研磨成浆,迅速钝化脂肪氧化酶和抗营养因子,而所得豆奶产品基本无豆腥味。
干热钝化处理:在大豆压碎去皮的同时,蒸汽干热至100℃,可将脂肪氧化酶和抗营养因子钝化。冷却后,加水至再进行挤压蒸煮。并经干燥、冷却、磨粉等程序,即得风味较好的大豆粉。
热烫处理:全大豆经沸水热烫处理亦可以钝化脂肪氧化酶和抗营养因子。对于干燥大豆,用10倍量沸水,需加热20分钟。而用水已经浸泡了4小时的大豆,则热烫10分钟即可达到去腥味之目的。热烫处理时应剧烈搅拌,以促进热量的传递,增强脱豆腥味和钝化抗营养因子效果。
微波加热处理法:微波加热的特点是能有效地供给热能,但不改变大豆原料的含水量,并可迅速使温度升高,从而有效地钝化脂肪酸氧化酶和抗营养因子。经微波处理过的大豆基本无豆腥味。
普通加热法可有效去除不稳定性抗营养因子,但却无法去除热稳定性的大豆蛋白粉抗原及胃肠胀气因子,而目,经常会出现加热不足及过度等现象。加热不足不能消除抗营养因子,加热过度则会破坏氨基酸(赖氨酸、精氨酸和部分含硫氨基酸)和维生素;加热过程中还会引起氨基酸与碳水化合物反应,如赖氨酸和还原糖反应生成不溶性复合物,导致蛋白质消化率下降。针对普通加热法不足,本发明优选蒸汽加热处理和热风喷射钝化处理。热风喷射钝化技术与蒸汽加热处理具有热处理短时间短,既可以可使大豆蛋白粉中对热敏感的抗营养因子活性消除,还可以使蛋白质链展开,氨基酸残基暴露,使之易于被人体体内蛋白酶水解。同时避免长时间的加热引起氨基酸与碳水化合物反应,如赖氨酸和还原糖反应生成不溶性复合物,导致蛋白质消化率下降。
为了达到获得高品质的蛋白质,优选通过下述方法制备大豆蛋白粉,包括如下步骤:
①干式热处理:对脱脂大豆粉添加水后,干式热处理;
②提取:采用立式多功能动态提取罐提取,干式热处理后的大豆粉,添加蒸馏水后提取,在不断搅拌下进行煮沸,在这种水解和提取过程中,往往会产生泡沫,然后冷却至室温液相混合物;
③固液分离:液相混合物过滤或离心,得滤液或上清液;
④分解:把滤液或离心上清液煮沸,搅拌直至滤液变混浊并产生沉淀,煮沸时间应直到不再产生沉淀为止得分解液;⑤固液分离:采用离心过滤法、吸过滤法或脱水器将分解液固液分离,分离悬浮液中的颗粒体,得含可溶性组分的滤液;
⑥喷雾干燥:含可溶性组分的滤液加以喷雾干燥(进风温度190-200℃、排风温度85℃),得无腥味、不含抗营养因子的水溶性大豆蛋白粉。
上述步骤①干式热处理中所述对脱脂大豆粉添加2-5%蒸馏水后,放入旋转窑进行干式热处理,温度为110-120℃,时间需1-2小时;
上述步骤②提取中所述干式热处理后的大豆粉,添加蒸馏水后提取,料水比为1:6-10(优选1:8),在不断搅拌下进行煮沸达6小时以上,然后冷却至室温得液相混合物。在这种水解和提取过程中,往往会产生泡沫
上述③固液分离中所述液相混合物冷却后进行过滤,或冷却后就倒入离心器中,将含有营养组分的液相和残渣分离开来得滤液或离心上清液。这种滤液或离心上清液是一种具有深色和-定香气的混浊性液体;除含有蛋白质和各种氨基酸外,还含有各种矿质成分(镁、钙、锰、铁等)、碳水化合物、卵磷脂及卵磷脂的分解产物、脑磷脂和肌醇的六价磷酸盐。
上述④分解中所述把滤液或离心上清液煮沸,连续搅拌使滤液变混浊并产生沉淀。该煮沸步骤可促进大豆有用的可溶性组分的溶解;连续搅拌步骤将滤液中的蛋白质和氨基酸分开。所述的煮沸时间应根据沉淀不再产生为止。优选煮沸3小时。为了控制此时所产生的泡沫,可调节加热的温度。
上述⑤固液分离中优选脱水器分离悬浮液中的颗粒体,得含可溶性组分的滤液。
上述⑥喷雾干燥种所述喷雾干燥,进风温度190-200℃、排风温度85℃上述步骤(2)中所述核心营养素的混合,其中核心营养素可市购,可根据原料的有效成分含量,计算原料用量,所述核心营养素原料用量=某核心营养素添加量÷原料中某核心营养素有效含量。
上述步骤(3)选择性营养素可根据原料的有效成分含量,计算原料用量,从市场上选择适宜的原料并确定其有效成分含量,按下列计算式折算:原料用量=某营养素添加量÷原料中某营养素有效含量。
上述步骤(4)蛋白质粉,核心营养素、选择性营养素按照比例混合,得粉末:
上述步骤(5)制粒:采用干法或湿法制粒,优选干法制粒,加入辅料、其它特殊需要的营养成分和适量的矫味剂、芳香剂;所述辅料与步骤(4)粉末的重量比为1-5:1(优选2.3:1);所述辅料包括于蔗糖、乳糖葡萄糖、淀粉、纤维素等。
上述步骤(6)中灌装:在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压孕妇及乳母用营养补充剂颗粒,密封盖通过热合等方式和容器结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
本发明还提供了该孕妇及乳母用营养补充剂在减少孕期并发症贫血的应用。
本发明的有益效果通过下述试验例阐述
试验例一孕妇及乳母缺铁性贫血及其防治试验
组方:
治疗方法:10例医院诊断为孕妇贫血的自愿者(排除病例非缺铁性贫血,或缺铁性贫血极重度者;过敏体质及对本药过敏者;合并心血管、脑血管、肝、肾及造血***其他严重原发性疾病,精神病患者;原发病未控制,持续出血所致贫血),年齡冲服上述营养补充剂,每日2次,每次1粒,30天为1个疗程,服药期间均不服用其他升血、补铁药物。
疗效标准:显效(临床症状明显好转,贫血程度分级由重度转为轻度,改善2级以上)、有效(临床症状有好转,贫血程度改善1级)、无效(临床症状及贫血程度无改善)。
临床观察表明,上述营养补充剂治疗孕妇缺铁性贫血,有效9例,其中显效6例。
试验例二孕期不同阶段选用营养素补充剂对孕鼠的影响
组方:
动物实验
成年健康清洁级雌性大鼠(Wistar)75只(体重210~230g),雄性大鼠30只(280~300g)。雌雄大鼠数量按2:1合笼,共获得孕鼠50只。根据给予样品时间的不同,将受孕大鼠分为孕前组(即:在交配前1周开始灌服样品)、孕早期组、孕中期组、孕晚期和对照组共5组,每组10只。按0.1g/kg.bw经灌胃给予上述营养补充剂,灌胃量为1.0ml/kg.bw对照组灌服等量的生理盐水。(2)每隔3天称量孕鼠的摄食量及体重。记录自然分娩的胎仔总数、活胎数、死胎数、畸胎数,测量其生长指标:身长(头臀长)、尾长、体重、头重。(3)采集孕鼠血液,分离血清,采用原子吸收分光光度法测定钙、镁、铁、锌的含量。(4)称量胎仔组织并消化,测定胎仔组织中钙、镁、铁、锌的含量。
动物实验结果显示,孕前组、孕早期组的孕鼠体重增长量在孕早期阶段明显高于对照组(P<0.05);孕中期时给予上述营养补充剂的孕鼠体重总增重量显著高于其他各组(P<0.05)。由各组产仔数量可见,给予上述营养补充剂的各组孕鼠产仔数多于对照组,差异有统计学意义(P<0.05)。孕期给予上述营养补充剂的各组胎仔组织中钙含量均高于对照组和孕前补充组(P<0.05);孕前组和孕中期组的胎仔组织镁含量高于对照组(P<0.01,P<0.05);孕晚期组的锌含量高于其他各组(P<0.05)。
试验例三抗营养因子钝化程度测定方法
进行热处理时,必须保证热处理的强度适宜。加热不足则抗营养因子破坏不够;加热过度则氨基酸利用率下降,会降低蛋白质的生物学效率。实际生产中多以测定脲酶活性判断胰蛋白因子的钝化程度,反应加热不足;釆用蛋白质溶解度作为判断蛋白粉加热过度的指标。
脲酶活性测定:采用纳氏试剂测定营养补充剂(蛋白粉)中脲酶活性的最适条件为:波长415nm,显色剂用量1mL,尿素浓度3%,反应温度35℃,反应时间7min。营养补充剂(蛋白粉)中脲酶的最佳作用pH为7.0,最适反应温度为35℃,脲酶在25~40℃之间贮存3h有较好的热稳定性,酶活保留率在80%以上。利用Lineweaver-Burk双倒数作图法求得脲酶的Vmax为0.17mmol/min,Km为0.017mol/L。
蛋白质溶解性测定:称取经研细(60目)后的1.5g蛋白粉于250mL烧杯中,加入75mL,0.2%KOH溶液,在磁力搅拌器中搅拌20min。再将50mL液体转至离心管中,用每分钟2700r速度离心10分钟。吸取上清液15mL,用凯氏定氮法测定其中的蛋白质含量。此含量相当于0.3克原样本中溶解的蛋白质量。
蛋白质溶解度(PS)按下式计算:
PS(%)=(V-V0)*C*0.014*6.25/0.3*100%
式中:
PS——蛋白质溶解度,%;
C——盐酸标准溶液浓度,mol/L;
V——滴定试样时所需标准酸溶液体积(mL)
V0——滴定空白时所需标准酸溶液体积(mL)
当PS>85%时,则认为蛋白粉加热处理不足;而当PS<75%时,则认为蛋白粉加热处理过度;而PS在75%~85%左右时,则认为蛋白粉的质量较好。
结果表,8
表8热风喷射钝化温度对抗营养因子活性影响
大豆蛋白粉序号 | 温度(℃) | 脲酶活性 | 蛋白质溶解度 |
1 | 200 | 3 | 91% |
2 | 230 | 0 | 85% |
3 | 300 | 0 | 82% |
4 | 310 | 0 | 80% |
5 | 320 | 0 | 75% |
结果,本发明在230-310℃的热风直接喷涂处理大豆蛋白粉,喷射钝化效果好,大豆蛋白粉中对热敏感的抗营养因子活性消除率高。
试验例四包装材料选择
从食品包装角度考虑,用本发明载明的胶囊这种形式作为载体比其他形式的货架期更长。货架期对食品生产企业和消费者都是至关重要的。本发明针对食品货架期的影响因素(产品本身及其功能、环境和包装材料等)采取了相应的措施。(1)产品货架期受产品的微生物、酶类和生化反应的影响。微生物自身产生的一些有害物质或微生物利用了产品中的某些营养成分生成其它物质,从而影响了产品的货架期。本发明的营养补充剂粉(颗粒)在分装前采用了相应的灭菌措施,在符合GMP要求的净化车间进行分装,在充满惰性气体的太空舱中进行密封,确保产品本身无微生物污染。大量的资料显示酶的作用是导致货架期问题的重要原因,本发明的营养补充剂粉(颗粒)在分装前采用了相应的酶高温灭活措施,确保产品本身无活性酶存在。生物化学方面的变化着重表现在氧化反应上,生化反应主要影响产品的外观,风味和口感。本发明的营养补充剂粉(颗粒)在充满惰性气体的太空舱中进行密封,胶囊采用耐高温、不透气的材料聚乙烯PE、聚丙烯PP(熔点高达167℃)、可发性聚苯乙烯EPS(耐热变形温度达280℃以上)、PEN/PET聚乙烯萘酚树脂、含高阻隔性材料的乙烯-乙烯醇共聚物EVOH、聚偏氯乙烯PVDC、尼龙MXD6,硅氧化物蒸镀膜等的多层复合材料中的中一种或一种,密封盖包括三层密封膜,三层密封膜由内向外分别为CPP膜、铝膜和PET膜。经密封盖热耦合密封的胶囊能确保产品本身无氧气,不会发生氧化还原反应。(2)影响产品货架期的环境因素有:保存温度,相对湿度,水分含量等。(3)不同的包装材料其透气性、密封性、透光性、阻湿性等都不同,从而影响产品的货架期。本发明的营养补充剂粉(颗粒)胶囊采用耐高温、不透气的材料,包括但不限于:聚乙烯PE、聚丙烯PP(熔点高达167℃)、可发性聚苯乙烯EPS(耐热变形温度达280℃以上)、PEN/PET聚乙烯萘酚树脂、含高阻隔性材料的乙烯-乙烯醇共聚物EVOH、聚偏氯乙烯PVDC、尼龙MXD6,硅氧化物蒸镀膜等的多层复合材料中的一种或几种,优选聚乙烯PE、聚丙烯PP。密封盖包括三层密封膜,三层密封膜由内向外分别为CPP膜、铝膜和PET膜。经密封盖热耦合密封的胶囊密封性好,确保不透气、不透光、阻湿性能好。见下表9、10:
表9
表10
稳定性 | 有效期 | 运输 | 保藏 | |
营养补充剂胶囊 | 好 | 2年以上 | 方便 | 容易 |
其它营养补充剂粉 | 一般 | 1年以下 | 不方便 | 不容易 |
综上所述本发明的产品还有如下特点
(1)方便。操作简单,任何一个新手都能轻松制作一杯安全、热腾腾的孕妇及乳母用营养补充剂。无需繁琐的清洁,做好孕妇及乳母用营养补充剂,直接回收容器就可以了。
(2)安全。选择优质的原辅料,在符合GMP要求的厂房内,采用类似于药品最严格的标准制程,通过国际先进的太空舱技术包装孕妇及乳母用营养补充剂颗粒,并填入氮气或二氧化碳等的革命性***,压倒目前所有一切的生产技术。不用拆包装直接放进机器,冲煮、萃取完后也方便回收。
(3)新鲜。胶囊是独立包装的,充氮,铝泊密封包装,每打开每一杯都是新鲜的。完全密封充氮气包装的保护下,能有效的保持孕妇及乳母用营养补充剂的新鲜,防止氧化,使保存期到达2年之久,因为他可以穿越2年的时间,可以到达国际空间站的距离,因此称他为太空食品,时空胶囊。
(4)品质稳定。孕妇及乳母用营养补充剂胶囊是在同样的生产线上,自动化填压,可以保证每杯孕妇及乳母用营养补充剂的品质稳定。
(5)热腾腾。通过高压沸水冲煮、萃取,得到的是热腾腾的孕妇及乳母用营养补充剂。
附图说明
图1为本发明容器的结构示意图;
图2为本发明容器内的底部结构示意图;
图3为本发明容器的密封盖结构示意图。
具体实施方式
实施例1本发明容器的结构
如图1所示,本发明容器包括容器本体1,所述容器本体1的顶部设有密封盖2,底部设有出口3,所述出口3被密封材料密封,所述容器本体1的外侧壁上设有斜凹槽4和卡槽5,所述容器本体1的内侧壁上与所述斜凹槽4相对应的部位为凸棱。斜凹槽4与凸棱一起构成外凹内凸的结构。本发明在使用的时候,容器本体1内部用来盛放咖啡粉或奶茶粉等内容物,所述卡槽5用来与外部设备(其对容器进行冲煮作业)进行衔接固定。
本发明容器,其中所述斜凹槽4呈倒人字形布置,与所述斜凹槽4相对应的凸棱也呈倒人字形布置。在容器本体1的内侧壁上设置倒人字形凸棱,能够使进入容器本体1内部的热水对内容物进行更加充分的搅拌。
如图2所示,本发明容器,其中所述容器本体1的底部设有螺旋凹槽6,所述螺旋凹槽6的一端紧贴容器本体1的内侧壁布置,另一端延伸至出口3。容器本体1的底部呈漏斗形,当汤液沿着容器本体1的内侧壁流到底部时,汤液沿着螺旋凹槽6流到出口3位置,流动过程中,在螺旋凹槽6的作用下,汤液发生旋转,进一步增强热水与内容物的混合程度。
当汤液汇集在容器本体1底部的出口位置时,此处的密封材料能够被设备的顶针刺穿,冲煮好的汤液从此处流出。
本发明容器,其中所述容器本体1内的顶部和底部分别设有一过滤器7。过滤器7为纸质过滤器,能够过滤水和内容物中的大颗粒、杂质等;也可以无过滤器,无过滤器,只影响外观和口感,不影响营养和口味。
如图3所示,本发明容器,其中所述密封盖2包括三层密封膜,三层密封膜由内向外分别为CPP膜201、铝膜202和PET膜203。其中,CPP膜201能够建立密封的首道屏障,铝膜202完全隔离水和空气,PET膜203能够加强密封效果。
本发明容器的的内侧壁上设有斜凸棱,当热水从顶部注入容器本体1内时,热水能够沿着凸棱流动,增强了水流对内容物的搅拌作用,从而使热水与内容物混合得更加充分,避免了内容物的浪费。
本发明中的容器本体1的上下两面可被特殊结构的穿刺头刺破;可耐15BAR的沸水冲煮,实现萃取功能;容器形状使在沸水冲煮时,容器内可产生涡流,加速容器内物质的溶解;可在与之相匹配的特殊功能机器(即上面提到的设备)里旋转,带动容器内溶液旋转混合,加速容器内物质的溶解和混合均匀。
容器本体1可置于特定的机器内,通过机器的特殊装置带动容器旋转,加速容器的内容物溶解。该容器的器壁被压制成具有特殊“倒人字型”内陷结构,容器的底部被压制成具有特殊螺旋状内陷结构,通过特定机器的特殊热水冲头冲热水时,能产生漩涡流(如图2),有助于胶囊内容物的溶解和混合。
容器本体1内的上下设置纸质过滤器7,过滤水和内容物中的大颗粒、杂质等,中间放置经过序处理的内容物,密封盖2通过热合等方式和容器本体1结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体,起到延长保质期再次灭菌的作用。需要冲煮汤液时,把这种容器放入专用的机器内(如胶囊式咖啡机或胶囊豆浆机)内,机器的刺破针将密封盖2刺破,高温高压水进入容器本体1内溶解内容物,经过过滤器,进入另一端刺入容器的刺破针,通过汇集到出口,从出口3流入杯中形成一杯浓香美味的营养补充剂、咖啡或豆浆。整个过程在1、2分钟内完成。使用后的容器直接废弃,机器不直接接触里面的物质,无需清洗机器。简单方便,省时省力,无需清洗机器。
实施例2不含抗营养因子优质蛋白质粉制备
①干式热处理:对脱脂大豆粉添加2%蒸馏水后,放入旋转窑进行干式热处理,温度为110℃,时间需2小时;
②提取:采用立式多功能动态提取罐提取,干式热处理后的大豆粉,添加蒸馏水后提取,料水比为1:8。在不断搅拌下进行煮沸达6小时以上,在这种水解和提取过程中,往往会产生泡沫。然后冷却至室温。
③固液分离:当液相混合物冷却后进行过滤,或冷却后就倒入离心器中,将含有营养组分的液相和残渣分离开来。
④分解:把滤液加以煮沸,以促进大豆有用的可溶性组分的溶解;为了把滤液中的蛋白质和氨基酸分开,将这种滤液在压热锅内煮沸,并连续搅拌。此时,滤液变混浊并产生沉淀,煮沸时间应直到不再产生沉淀为止,一般需3小时左右。
⑤固液分离:采用离心过滤法、分离悬浮液中的颗粒体,得含可溶性组分的滤液。
⑥喷雾干燥:含可溶性组分的滤液加以喷雾干燥(进风温度190-200℃、排风温度85℃),得无腥味、不含抗营养因子的水溶性大豆蛋白粉。
实施例3不含抗营养因子优质蛋白质粉制备
①干式热处理:对脱脂大豆粉添加5%蒸馏水后,放入旋转窑进行干式热处理,温度为120℃,时间需1小时;
②提取:采用立式多功能动态提取罐提取。干式热处理后的大豆粉,添加蒸馏水后提取,料水比为1:10。在不断搅拌下进行煮沸达6小时以上;
③固液分离:当液相混合物冷却后进行过滤,或冷却后就倒入离心器中,将含有营养组分的液相和残渣分离开来;
④分解:把滤液加以煮沸,以促进大豆有用的可溶性组分的溶解;为了把滤液中的蛋白质和氨基酸分开,将这种滤液在压热锅内煮沸,并连续搅拌。此时,滤液变混浊并产生沉淀,煮沸时间应直到不再产生沉淀为止,需3小时;
⑤固液分离:采用离心过滤法、吸过滤法或脱水器,优选脱水器,分离悬浮液中的颗粒体,得含可溶性组分的滤液。
⑥喷雾干燥:含可溶性组分的滤液加以喷雾干燥(进风温度190-200℃、排风温度85℃),得无腥味、不含抗营养因子的水溶性大豆蛋白粉。
实施例4不含抗营养因子优质蛋白质粉制备
购买符合要求的蛋白粉,过筛后,迅速与热蒸汽混合,使水分达到 于90-100℃常压加热处理分钟,迅速降温,即可使脂肪氧化酶失活,成品风味较好,消除了蛋白质粉中腥味、钝化抗营养因子,并提高了产品的营养价值。高压水蒸汽处理是将大豆粉碎过筛后,至压力锅中,温度110-130℃、10-20分钟,压力80-110kPa,可消除蛋白质粉中腥味、钝化抗营养因子。
实施例5不含抗营养因子优质蛋白质粉制备
购买符合要求的蛋白粉,在温度为232-310℃的热风直接喷射处理大豆蛋白粉,可将脂肪氧化酶和抗营养因子钝化。
实施例6不含抗营养因子优质蛋白质粉制备
购买符合要求的蛋白粉,过筛后,至压力锅中,温度110-130℃、10-20分钟,压力80-110kPa,可消除蛋白质粉中腥味、钝化抗营养因子。
实施例7
组分表
上表中孕妇用粉末混合均匀,采用优选干法制粒制得孕妇用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压孕妇用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
上表中乳母用粉末混合均匀,采用优选干法制粒制得乳母用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压乳母用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
实施例8
组分
上表中孕妇用粉末混合均匀,采用优选干法制粒制得孕妇用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压孕妇用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
上表中乳母用粉末混合均匀,采用优选干法制粒制得乳母用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压乳母用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
实施例9
上表中孕妇用粉末混合均匀,采用优选干法制粒制得孕妇用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压孕妇用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
上表中乳母用粉末混合均匀,采用优选干法制粒制得乳母用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压乳母用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
实施例10
上表中孕妇用粉末混合均匀,采用优选干法制粒制得孕妇用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压孕妇用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
上表中乳母用粉末混合均匀,采用优选干法制粒制得乳母用营养补充剂颗粒,在具有无毒的惰性气体(氮气或二氧化碳等)保护的生产线上,采用机器自动化定量填压乳母用营养补充剂颗粒,密封盖通过热合等方式和容器(实施例1)结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
前述对本发明的具体示例性实施方案的描述是为了说明和例证的目的。这些描述并非想将本发明限定为所公开的精确形式,并且很显然,根据上述教导,可以进行很多改变和变化。对示例性实施例进行选择和描述的目的在于解释本发明的特定原理及其实际应用,从而使得本领域的技术人员能够实现并利用本发明的各种不同的示例性实施方案以及各种不同的选择和改变。本发明的范围意在由权利要求书及其等同形式所限定。
Claims (10)
1.一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于,是由营养补充剂和耐高温材料组成的容器构成;所述营养补充剂放入耐高温材料容器内,密封容器,容器内充填满惰性气体;所述营养补充剂包括下述重量份成分:
优质蛋白质 15~35份,
营养素 1~10份,
辅料 35~84份。
2.如权利要求1所述的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于,所述营养补充剂包括下述的重量份成分:
优质蛋白质 25~30份,
营养素 2~5份,
辅料 50~69份。
3.如权利要求1所述的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于:所述的优质蛋白质无腥味、不含抗营养因子。
4.如权利要求1所述的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于:所述营养素包括核心营养素和选择性营养素,其中核心营养素是由下述重量比组分构成
表1
其中,选择性营养素包括下述重量比成分一种以上。
表2
5.如权利要求4所述的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于:其中核心营养素是由下述重量比组分构成
表3核心营养素重量比
其中,选择性营养素重量比见表4
表4选择性营养素重量比:
6.如权利要求1所述的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于,所述的耐高温材料的容器的器壁被压制成具有特殊“倒人字型”内陷结构,容器的底部被压制成具有特殊螺旋状内陷结构,通过热水冲头冲热水时,能产生漩涡流,有助营养补充剂的溶解和混合。
7.如权利要求4所述的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于,所述容器的结构包括容器本体,所述容器本体的顶部设有密封盖,底部设有出口,所述出口被密封材料密封,所述容器本体的外侧壁上设有斜凹槽和卡槽,所述容器本体的内侧壁上与所述斜凹槽相对应的部位为凸棱;所述斜凹槽呈倒人字形布置,与所述斜凹槽相对应的凸棱也呈倒人字形布置;所述容器本体的底部设有螺旋凹槽,所述螺旋凹槽的一端紧贴容器本体的内侧壁布置,另一端延伸至出口。
8.如权利要求1所述的一种即冲即食的孕妇及乳母用营养补充剂制品,其特征在于,所述耐高温90℃-150℃,所述耐高温材料为聚乙烯PE、聚丙烯PP、可发性聚苯乙烯EPS、PEN/PET聚乙烯萘酚树脂、含高阻隔性材料的乙烯-乙烯醇共聚物EVOH、聚偏氯乙烯PVDC、尼龙MXD6,硅氧化物蒸镀膜中一种或几种。
9.一种即冲即食的孕妇及乳母用营养补充剂制品的制备方法,其特征在于包括如下步骤:
(1)无腥味、不含抗营养因子优质蛋白质粉制备:
(2)核心营养素预混合粉制备:
(3)选择性营养素预混合粉制备:
(4)步骤(1)蛋白质粉和步骤(2)核心营养素和步骤(3)选择性营养素混合,得粉末:
(5)制粒:步骤(4)粉末与辅料混合、制粒;
(6)灌装:将制备好的孕妇及乳母用营养补充剂颗粒装入耐高温耐高压容器内,密封。
10.如权利要求9所述的一种即冲即食的孕妇及乳母用营养补充剂制品的制备方法,其特征在于包括如下步骤:
(1)无腥味、不含抗营养因子优质蛋白质粉制备,采用如下任一种方式:
A.市购大豆蛋白粉必须符合GB/T 22493-2008要求,优质蛋白质粉的添加量可根据优质蛋白质粉原料中的蛋白质成分的含量,计算原料用量,所述优质蛋白质粉原料用量=蛋白质添加量÷优质蛋白质粉原料中的蛋白质成分的含量,采用热处理方法消除蛋白质粉中腥味、钝化抗营养因子,所述热处理方法如下任一种:
常压水蒸汽处理:将大豆粉碎过筛后,迅速与热蒸汽混合,使水分达到于90-100℃常压加热处理迅速降温,即可使脂肪氧化酶失活,成品风味较好,消除了蛋白质粉中腥味、钝化抗营养因子,并提高了产品的营养价值;
高压水蒸汽处理:是将大豆粉碎过筛后,至压力锅中,温度110-130℃、10-20分钟,压力80-110kPa,可消除蛋白质粉中腥味、钝化抗营养因子;
热风喷射钝化技术:温度为232-310℃的热风直接喷射处理大豆蛋白粉,可将脂肪氧化酶和抗营养因子钝化;
或B.大豆蛋白粉的制备步骤包括:
①干式热处理:对脱脂大豆粉添加蒸馏水后,放入旋转窑进行干式热处理;
②提取:采用立式多功能动态提取罐提取,干式热处理后的大豆粉,添加蒸馏水后提取,在不断搅拌下进行煮沸达6小时以上,然后冷却至室温得液相混合液;
③固液分离:当液相混合物冷却后进行过滤,或冷却后就倒入离心器中,将含有营养组分的液相和残渣分离开来,得滤液或离心上清液;
④分解:把滤液或离心上清液加以煮沸,以促进大豆有用的可溶性组分的溶解;并连续搅拌直至滤液变混浊并产生沉淀,煮沸时间应直到不再产生沉淀为止;
⑤固液分离:采用离心法、过滤法或脱水器,分离悬浮液中的颗粒体,得含可溶性组分的滤液;
⑥喷雾干燥:含可溶性组分的滤液加以喷雾干燥进风温度190-200℃、排风温度85℃,得无腥味、不含抗营养因子的水溶性大豆蛋白粉。
(2)核心营养素预混合粉制备:核心营养素可市购,可根据原料的有效成分含量,计算原料用量,所述核心营养素原料用量=某核心营养素添加量÷原料中某核心营养素有效含量;
(3)选择性营养素预混合粉制备:根据原料的有效成分含量,计算原料用量,从市场上选择适宜的原料并确定其有效成分含量,按下列计算式折算:原料用量=某营养素添加量÷原料中某营养素有效含量;
(4)步骤(1)蛋白质粉和步骤(2)核心营养素和步骤(3)选择性营养素混合,得粉末:
(5)制粒:采用干法或湿法制粒,加入辅料、其它特殊需要的营养成分和适量的矫味剂、芳香剂;所述辅料与粉末的重量比为1-5:1,所述辅料包括于蔗糖、乳糖葡萄糖、淀粉、纤维素;
(6)灌装:在具有无毒的惰性气体保护的生产线上,采用机器自动化定量填压孕妇及乳母用营养补充剂颗粒,密封盖通过热合等方式和容器结合,确保密封,容器内充填满无毒的氮气或二氧化碳等惰性气体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710437705.3A CN107242576A (zh) | 2017-06-12 | 2017-06-12 | 一种即冲即食的孕妇及乳母用营养补充剂制品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710437705.3A CN107242576A (zh) | 2017-06-12 | 2017-06-12 | 一种即冲即食的孕妇及乳母用营养补充剂制品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107242576A true CN107242576A (zh) | 2017-10-13 |
Family
ID=60019088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710437705.3A Pending CN107242576A (zh) | 2017-06-12 | 2017-06-12 | 一种即冲即食的孕妇及乳母用营养补充剂制品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107242576A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107594540A (zh) * | 2017-11-05 | 2018-01-19 | 耿德铨 | 助孕育营养品复合粉及其制备方法 |
CN107890115A (zh) * | 2017-11-01 | 2018-04-10 | 苏州大学 | 一种促进妊娠期糖尿病滞长胎儿生长的营养粉及制备方法与应用 |
CN109288067A (zh) * | 2018-10-18 | 2019-02-01 | 德瑞美医药生物技术盐城有限公司 | 一种助孕保胎的营养制剂 |
CN110122885A (zh) * | 2019-06-06 | 2019-08-16 | 南通光合生物技术有限公司 | 快速分散易冲调性的蛋白粉 |
CN114651988A (zh) * | 2022-03-23 | 2022-06-24 | 浙江科露宝食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1463745A (zh) * | 2002-06-14 | 2003-12-31 | 丁强 | 一种全元营养素补充剂 |
CN102459029A (zh) * | 2009-06-04 | 2012-05-16 | 米塔卡有限责任公司 | 利用咖啡及可溶产品制备饮料的刚性盒部件 |
CN203767334U (zh) * | 2014-04-22 | 2014-08-13 | 浙江爱仕达生活电器有限公司 | 一种饮料胶囊 |
CN106135425A (zh) * | 2015-04-01 | 2016-11-23 | 郑路生 | 一种适合孕哺期食用的牛奶蛋白质粉 |
-
2017
- 2017-06-12 CN CN201710437705.3A patent/CN107242576A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1463745A (zh) * | 2002-06-14 | 2003-12-31 | 丁强 | 一种全元营养素补充剂 |
CN102459029A (zh) * | 2009-06-04 | 2012-05-16 | 米塔卡有限责任公司 | 利用咖啡及可溶产品制备饮料的刚性盒部件 |
CN203767334U (zh) * | 2014-04-22 | 2014-08-13 | 浙江爱仕达生活电器有限公司 | 一种饮料胶囊 |
CN106135425A (zh) * | 2015-04-01 | 2016-11-23 | 郑路生 | 一种适合孕哺期食用的牛奶蛋白质粉 |
Non-Patent Citations (3)
Title |
---|
关海宁等: "《龙江地产农产品加工技术》", 31 January 2013, 黑龙江大学出版社 * |
张海臣: "脱腥保溶大豆蛋白粉的研究", 《郑州粮食学院学报》 * |
靳烨: "《畜禽食品工艺学》", 31 March 2004 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107890115A (zh) * | 2017-11-01 | 2018-04-10 | 苏州大学 | 一种促进妊娠期糖尿病滞长胎儿生长的营养粉及制备方法与应用 |
CN107594540A (zh) * | 2017-11-05 | 2018-01-19 | 耿德铨 | 助孕育营养品复合粉及其制备方法 |
CN109288067A (zh) * | 2018-10-18 | 2019-02-01 | 德瑞美医药生物技术盐城有限公司 | 一种助孕保胎的营养制剂 |
CN110122885A (zh) * | 2019-06-06 | 2019-08-16 | 南通光合生物技术有限公司 | 快速分散易冲调性的蛋白粉 |
CN114651988A (zh) * | 2022-03-23 | 2022-06-24 | 浙江科露宝食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107242576A (zh) | 一种即冲即食的孕妇及乳母用营养补充剂制品及其制备方法 | |
CN101297685B (zh) | 功能豆腐脑粉及其制作方法 | |
CN106490605A (zh) | 一种妊娠高血压专用型临床营养配方及其制备方法 | |
CN101703227A (zh) | 催乳汤 | |
CN101889670A (zh) | 麦麸、胚芽杂粮熟食粉及其制备方法 | |
CN105494577A (zh) | 学龄前儿童食用的营养易消化饼干 | |
CN108967795A (zh) | 一种鹿血肽固体饮品 | |
CN103169084B (zh) | 一种促进产后恢复的组合物及其制备方法 | |
CN111771970A (zh) | 有助于养胃、护胃的组合物及其制备方法 | |
CN101836679A (zh) | 一种高效减肥奶茶及其制作方法 | |
CN101856090B (zh) | 婴幼儿消食开胃因子营养食品颗粒的制备方法 | |
CN105795279A (zh) | 一种人体营养食补的食品饮料配方 | |
CN103392982B (zh) | 排毒养颜奶粉 | |
CN103622090A (zh) | 一种能强肾健体的新型粉糊 | |
CN107821619A (zh) | 一种高品质豆花的生产工艺 | |
CN107302999A (zh) | 麦冬保健营养粉 | |
CN113208079A (zh) | 一种具有保健功能的冻干鸡汤及其制备方法 | |
CN113973921B (zh) | 一种有利于快速吸收蛋白的羊奶粉及其制备方法 | |
CN107212345A (zh) | 一种即冲即食鸡汤制品及其制备方法 | |
CN109567180A (zh) | 一种可用于女性经、孕、产、乳期的营养品及其制备方法 | |
CN104472762A (zh) | 一种用于大米烹饪时强化营养的红茶组合物 | |
CN108576234A (zh) | 提高产妇泌乳量的食品及其制备方法 | |
CN105995989A (zh) | 一种针对婴儿缺铁的食品及其制备方法 | |
CN106387423A (zh) | 一种用于仔猪断奶的仔猪饲料 | |
CN106616640A (zh) | 一种补气溢血营养藕粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171013 |
|
RJ01 | Rejection of invention patent application after publication |